Headquartered in Scottsdale, Arizona, PathogenDx's mission is to become the new standard in molecular-based testing through widespread adoption of its advanced microarray testing platform for the human diagnostics, food and agricultural industries. To learn more, please visit About PathogenDx The test is ideal for small and medium-sized clinical/CLIA labs in need of low-cost testing, especially ideal for rural areas. Global distribution of diagnostic tests like our DetectX-Rv test is crucial in helping limit the spread of COVID-19 and its variants."ĭetectX-Rv uses standard off-the-shelf lab equipment and was developed to meet daily test volumes without incurring economic loss on unused wells. The virus will continue to mutate and we need to be able to identify if an infected patient has a particular variant in order to provide the most effective clinical and therapeutic treatment. "Although we are in the second year of the pandemic and vaccine distribution has greatly improved, COVID-19 and its variants persist in our global community.
"Receiving the CE-IVD Mark for our DetectX-Rv test is a massive milestone for our company and will not only help detect COVID-19 in Europe as the pandemic sweeps on, but with the company's follow-on Detect-Cv Clade variant test helps identify the Variant of Concern and/or Variant of Interest from any positive result processed either from DetectX-Rv or any other molecular platform" said Milan Patel, Co-founder and CEO of PathogenDx. The test also ensures 100% specificity by analyzing the sample in triplicate for each patient swab within each array, not just once as conducted in currently approved COVID-19 tests. Its multiplex system also has the capability of pooled sample testing for the detection of SARS-CoV2 in multiple samples at one time, dramatically increasing COVID-19 testing throughput.ĭetectX-Rv delivers superior accuracy based on its proprietary technology of analyzing dozens of probes in COVID-19 regions of the viral genome, delivering a Limit of Detection of 1,000 copies/mL. PathogenDx's DetectX-Rv microarray utilizes nasopharyngeal swabs and nasal aspirate or fluid to detect SARS-CoV2 within three hours after RNA extraction, and has received Emergency Use Authorization (EUA) from the U.S.
The CE-IVD mark is in conformance with the European Union In Vitro Diagnostic Directive 98/79/EC. SCOTTSDALE, Ariz., J/PRNewswire/ - PathogenDx, Inc., an Arizona based biotechnology company which has developed a multiplexed microarray DNA-based pathogen testing platform, today announced that it has received the CE-IVD Mark for the sale and distribution of its patented DetectX-Rv Microarray Assay for COVID-19 testing across Europe.
0 kommentar(er)
